JP2005535588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535588A5 JP2005535588A5 JP2004501452A JP2004501452A JP2005535588A5 JP 2005535588 A5 JP2005535588 A5 JP 2005535588A5 JP 2004501452 A JP2004501452 A JP 2004501452A JP 2004501452 A JP2004501452 A JP 2004501452A JP 2005535588 A5 JP2005535588 A5 JP 2005535588A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- amino acid
- acid sequence
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37635102P | 2002-04-29 | 2002-04-29 | |
| PCT/EP2003/004425 WO2003093313A2 (en) | 2002-04-29 | 2003-04-28 | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010130425A Division JP2010202664A (ja) | 2002-04-29 | 2010-06-07 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005535588A JP2005535588A (ja) | 2005-11-24 |
| JP2005535588A5 true JP2005535588A5 (cg-RX-API-DMAC10.html) | 2006-07-06 |
Family
ID=29401334
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501452A Pending JP2005535588A (ja) | 2002-04-29 | 2003-04-28 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
| JP2010130425A Pending JP2010202664A (ja) | 2002-04-29 | 2010-06-07 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010130425A Pending JP2010202664A (ja) | 2002-04-29 | 2010-06-07 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8586538B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1497330B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2005535588A (cg-RX-API-DMAC10.html) |
| AT (1) | ATE463514T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2003227687B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2484155C (cg-RX-API-DMAC10.html) |
| DE (1) | DE60332011D1 (cg-RX-API-DMAC10.html) |
| DK (1) | DK1497330T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2343681T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2003093313A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004003144A2 (en) | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| EP1454632A1 (en) * | 2003-02-07 | 2004-09-08 | Aventis Behring GmbH, Intellectual Property/Legal | Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| WO2006003183A1 (de) * | 2004-07-02 | 2006-01-12 | Alois Jungbauer | Peptide zur blockierung von fviii-inhibitoren |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| JP2009274958A (ja) | 2006-08-31 | 2009-11-26 | Nara Prefecture | 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体 |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| JP5674650B2 (ja) * | 2008-06-04 | 2015-02-25 | バイエル・ヘルスケア・エルエルシー | フォン・ヴィレブランド病の処置のためのｆｖｉｉｉ変異タンパク質 |
| EP2865760B1 (en) | 2008-06-24 | 2017-10-11 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| JP5394864B2 (ja) * | 2009-09-10 | 2014-01-22 | アスモ株式会社 | モータ |
| WO2011095604A1 (en) * | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
| CN104788557A (zh) | 2010-09-15 | 2015-07-22 | 诺沃—诺迪斯克有限公司 | 具有减少的细胞摄取的因子viii变体 |
| US9458223B2 (en) | 2012-02-15 | 2016-10-04 | Csl Behring Gmbh | Von willebrand factor variants having improved factor VIII binding affinity |
| EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| DK3164150T3 (da) | 2014-07-02 | 2021-02-08 | CSL Behring Lengnau AG | Modificeret von willebrand-faktor |
| SG11201706659WA (en) | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| CA2986626A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
| CA2986625A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Methods for preparing modified von willebrand factor |
| SG11201805494WA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated von willebrand factor |
| AU2017204955B2 (en) | 2016-01-07 | 2021-04-01 | CSL Behring Lengnau AG | Mutated truncated von Willebrand Factor |
| DK3538133T3 (da) | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |
| JP2020504082A (ja) | 2016-11-11 | 2020-02-06 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11507664A (ja) * | 1995-06-12 | 1999-07-06 | ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス | 第ｖｉｉｉ因子由来の第ｉｘ因子結合ペプチド及び血液凝固のインヒビターとしてのそれらの使用 |
| AU760678B2 (en) * | 1998-05-08 | 2003-05-22 | Stichting Sanquin Bloedvoorziening | Method for diagnosis and treatment of haemophilia a patients with an inhibitor |
| AT409335B (de) * | 1998-11-10 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen |
| DK1129186T4 (da) * | 1998-11-10 | 2017-02-06 | Stichting Sanquin Bloedvoorziening | Et faktor VIII-polypeptid med faktor VIII:C-aktivitet |
-
2003
- 2003-04-28 US US10/512,907 patent/US8586538B2/en not_active Expired - Fee Related
- 2003-04-28 AT AT03725109T patent/ATE463514T1/de active
- 2003-04-28 DK DK03725109.7T patent/DK1497330T3/da active
- 2003-04-28 WO PCT/EP2003/004425 patent/WO2003093313A2/en not_active Ceased
- 2003-04-28 CA CA2484155A patent/CA2484155C/en not_active Expired - Lifetime
- 2003-04-28 ES ES03725109T patent/ES2343681T3/es not_active Expired - Lifetime
- 2003-04-28 DE DE60332011T patent/DE60332011D1/de not_active Expired - Lifetime
- 2003-04-28 AU AU2003227687A patent/AU2003227687B2/en not_active Ceased
- 2003-04-28 JP JP2004501452A patent/JP2005535588A/ja active Pending
- 2003-04-28 EP EP03725109A patent/EP1497330B1/en not_active Expired - Lifetime
-
2010
- 2010-06-07 JP JP2010130425A patent/JP2010202664A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9498514B2 (en) | Systems, compositions, and methods for transplantation and treating conditions | |
| Seifert et al. | Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies | |
| JP6356106B2 (ja) | 凍結乾燥された治療用ペプチボディ製剤 | |
| JP4175668B2 (ja) | Ｏｂ融合タンパク質組成物および方法 | |
| IL283561A (en) | Methods for treating ocular diseases | |
| JP2010202664A5 (cg-RX-API-DMAC10.html) | ||
| Machold et al. | Adalimumab–a new TNF-α antibody for treatment of inflammatory joint disease | |
| JP2012523438A5 (cg-RX-API-DMAC10.html) | ||
| US20140031286A1 (en) | Angiotensin (1-7) Dosage Forms and Uses Thereof | |
| JP2008521426A5 (cg-RX-API-DMAC10.html) | ||
| US11993640B2 (en) | Treating inflammatory lung disease | |
| WO2003093313A3 (en) | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein | |
| JP2007500741A (ja) | 一時的処置のための短い半減期を有するｃ１インヒビター | |
| US8183201B2 (en) | Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin | |
| US20240335507A1 (en) | Therapeutic composition for use in the treatment of covid-19 and other cytokine storm associated disorders | |
| CA2233138A1 (en) | Inhibitors of integrin receptors and their therapeutical uses | |
| Frank | Hereditary angiodema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema | |
| JP2010512349A (ja) | 低出血性抗凝固性融合タンパク質の調製および使用 | |
| JP2020519658A (ja) | 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療 | |
| AU2017305856B2 (en) | Pharmaceutical formulations of C1 esterase inhibitor | |
| AU2016221627A1 (en) | Pharmaceutical formulations of C1 esterase inhibitor | |
| EP0333517A2 (en) | Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor | |
| JP5836968B2 (ja) | ＩｇＥ媒介性疾患の処置方法 | |
| JP2022066353A (ja) | 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法 | |
| JP2017513831A5 (cg-RX-API-DMAC10.html) |